Back to search results

Sleep and Performance Study with WISP Device

This study is exploring how sleep affects your brain's ability to clear waste and maintain memories, especially after poor sleep. Researchers are using new MRI (Magnetic Resonance Imaging) methods to understand the brain's waste clearance system, called the glymphatic system, in young adults. They want to see if a device called the Wireless Interface Sensor Pod (WISP) can improve brain function after poor sleep. The WISP is a headband that tracks brain waves and uses transcranial electrical stimulation (TES) to monitor and potentially improve deep sleep and waste clearance. You might be able to join if you are between 18 and 30 years old, physically and psychologically healthy, and usually get 6 to 10 hours of sleep with regular bedtimes. The study aims to enroll 16 participants, but its current status is unclear.

Study design
This interventional study will involve 16 participants who will either receive transcranial electrical stimulation (TES) via the WISP device or a sham (inactive) version of the device.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Brain imaging (Multimodal MRI) will be measured immediately after the intervention with sleep condition and TES.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07608614

Sleep and Performance

Recruiting
NAAges 18–30InterventionalTreatment
University of Washington
~16 participants
Updated 2026-05-27 on ClinicalTrials.gov
What's tested:Transcranial Electric StimulationSham Comparator

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Multimodal MRI
Measured over Immediately after the intervention with sleep condition and TES

Conditions

Sleep
Glymphatic System

Explore related trials

Cognitive DysfunctionGlymphatic SystemSleep

Where it's being run

1 sites across 1 states
Washington1

Study leadership

  • Jeffrey Iliff, PhD · PRINCIPAL_INVESTIGATOR · University of Washington

Who to contact

Yeilim Cho, MD
[email protected]
(206) 277-7207
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Subjects who have any type of non-MRI compatible bioimplant activated by mechanical, electronic, or magnetic means (e.g., cochlear implants, pacemakers, neurostimulators, biostimulators, electronic infusion pumps, etc.), because such devices may be displaced or malfunction.
Subjects who have any type of ferromagnetic bioimplant that could potentially be displaced.
Subjects who have cerebral aneurysm
Subjects who may have shrapnel imbedded in their bodies (such as from war wounds), metal workers and machinists (potential for metallic fragments in or near the eyes).
Minors (younger than 18 years)
Pregnant women ( Participants of childbearing potential will receive a urine pregnancy test. If the test is positive, the participant will be excluded)
Breastfeeding
Subjects who cannot adhere to the experimental protocols for any reason, or have an inability to communicate with the researcher.
no clinical disorders and/or illnesses, no psychiatric illnesses), as assessed by history and questionnaires
no alcohol during study and no normal excessive alcohol consumption assessed by questionnaire
No history of drug or alcohol abuse in the past year and no history of methamphetamine abuse, as assessed by questionnaires.
Not a dependent smoker or vaper, and not morning dependent on tobacco, nicotine, or cannabis, as assessed by questionnaire.
No history of moderate to severe brain injury, as assessed by questionnaire
No anti-psychotic medication for ADHD/ADD, as assessed by questionnaire
No previous adverse reaction to sleep deprivation, as assessed by questionnaire
Not vision-impaired unless corrected back to normal.
Not hearing impaired unless corrected to normal, as assessed by questionnaire
Not pregnant, as assessed by history and questionnaire
No sleep or circadian disorder, as assessed by questionnaires
No use of melatonin within 1 week of study enrollment
No travel across more than one time zone within one month of entering the study and no crossing times zones during study participation, as assessed by questionnaire.
No shift work within three months of entering the study and no shift work during duration study participation, as assessed by questionnaire.
epilepsy

What this trial measures

  • Multimodal MRIImmediately after the intervention with sleep condition and TES

    We will test whether enhancing slow-wave sleep using the AugNOD TES SO improves overnight glymphatic function, as measured by non-invasive multimodal MRI-based markers of glymphatic activity: (i) diffusion-based intravoxel incoherent motion (IVIM)-MRI assessing long-distance water transport (diffusion signal); (ii) fast functional MRI (f-MRI) measuring low-frequency vasomotor oscillations; (iii) T1/FLAIR-based assessment of MRI-visible perivascular spaces (MV-PVS), which serve as structural indicators of perivascular impairment; (iv) multi-echo arterial spin-labeling (ME-ASL)-MRI assessing glial-vascular water transport ; and (v) Magnetic Resonance Elastography (MRE) measuring brain tissue stiffness.